Literature DB >> 8870850

Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping.

F Barin1, Y Lahbabi, L Buzelay, B Lejeune, A Baillou-Beaufils, F Denis, C Mathiot, S M'Boup, V Vithayasai, U Dietrich, A Goudeau.   

Abstract

We investigated whether V3-binding assays might be useful to analyze human immunodeficiency virus type 1 (HIV-1) variants in different geographic regions. We showed that strong cross-reactivity between subtype-specific V3 peptides is almost inevitable in standard indirect enzyme-linked immunosorbent assays (EIA), impairing precise serological subtyping. We therefore developed a subtype-specific EIA (HIV-1 SSEIA) that uses the principle of blocking by an excess of peptide in the liquid phase. Using 231 serum samples collected from HIV-1-infected individuals in 10 different geographical areas from 4 continents, we showed that this approach detected the dominant subtype reactivity in more than 97% of the cases. Internal controls (0 and 100% blocking) were used for every sample such that comparative analysis was possible, independent of both the individual humoral response and the time of collection during the course of infection. This was validated by the excellent concordance of the serological profiles of couples and the temporal stability of the serological profile in individuals. The geographical distribution of the various subtypes in the SSEIA was in agreement with the present knowledge of the distribution of the various genotypes. Although the goal of this study was not an extensive seroepidemiological survey, our results showed that the various profiles in most of the regions were relatively homogeneous, but in central Africa there was a large diversity of serological profiles. Cluster analysis identified a limited number of V3 serogroups of serotypes within the HIV-1 group M. Five serogroups, some of them divided into subgroups, were identified and characterized by a mean serological profile. Our data confirmed that subtypes A and C, although being dissimilar genetic subtypes, present conserved antigenic properties in the V3 region, and that the D subtype is probably the most divergent within the group M (B Korber et al., J Virol 1994;68:6730). Cluster analysis showed a clear correlation between position within the dendrogram and geographical origin of the samples. This is further support for the reliability and thereof the usefulness of the SSEIA. This simple methodology may help facilitate the analysis of the distribution of various HIV-1 subtypes circulating in different populations and regions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8870850     DOI: 10.1089/aid.1996.12.1279

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  24 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

5.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG.

Authors:  M P de Baar; E C Timmermans; M Bakker; E de Rooij; B van Gemen; J Goudsmit
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

7.  Analysis of the antibody response to an immunodominant epitope of the envelope glycoprotein of a lentivirus and its diagnostic potential.

Authors:  Franca Mordasini; Hans-Rudolf Vogt; Marie-Luise Zahno; Ariane Maeschli; Chiara Nenci; Reto Zanoni; Ernst Peterhans; Giuseppe Bertoni
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping.

Authors:  G Murphy; F J Belda; C P Pau; J P Clewley; J V Parry
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

9.  Impact of HIV/Aids on Child Mortality before the Highly Active Antiretroviral Therapy Era: A Study in Pointe-Noire, Republic of Congo.

Authors:  Camille Lallemant; Gaston Halembokaka; Gaelle Baty; Nicole Ngo-Giang-Huong; Francis Barin; Sophie Le Coeur
Journal:  J Trop Med       Date:  2010-08-17

10.  Performance of the Liaison XL Murex HIV Ab/Ag test on clinical samples representing current epidemic HIV variants.

Authors:  Véronique Lemee; Marie Leoz; Manuel Etienne; Fabienne De Oliveira; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2014-06-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.